Simeprevir for the treatment of hepatitis C virus infection.

Article Details

Citation Copy to clipboard

Izquierdo L, Helle F, Francois C, Castelain S, Duverlie G, Brochot E

Simeprevir for the treatment of hepatitis C virus infection.

Pharmgenomics Pers Med. 2014 Aug 14;7:241-9. doi: 10.2147/PGPM.S52715. eCollection 2014.

PubMed ID

25206310 [ View in PubMed

]

Abstract

Simeprevir (TMC435, Olysio), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is highly effective and safe, with few adverse events. We discuss the specific features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, will be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be part of future treatment strategies.

DrugBank Data that Cites this Article

Drugs

Simeprevir

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Pitavastatin Simeprevir	The serum concentration of Pitavastatin can be increased when it is combined with Simeprevir.